In updating the combined knowledge on the roles that PKA, cAMP and EPAC play in the development and progression of prostate cancer (specifically with respect to its cross-talk with AR signalling) this review positions the cAMP signalling system as a key future area for development in the design of modern and targeted therapies for this disease. This evidence concerns the gene RAPGEF3 and prostate carcinoma.